Enanta Pharmaceuticals, Inc.

Good afternoon and welcome to Enanta Pharmaceuticals' first call. Second quarter ended March 31st, 2023 Financial Results Conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end of the preparing marks. Please be advised that this call is being recorded. I would now like to turn the call over to Jennifer Vieira, Investor Relations. Please go ahead.

Thank you, Operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter 2023 financial results was issued this afternoon and is available on our website. A news release with top line data from our SPRINT clinical trial was also issued this afternoon and can be found on our website as well. Slides from today's webcast will be available on our website after the call ends. On the call today are Dr. Jay Lulai, our President and Chief Executive Officer, Dr. Scott Rottinghaus, our Chief Medical Officer, Paul Mellett, our Chief Financial Officer, and Dr. Tara Kiefer, our Senior Vice President of New Product Strategy and Development. Before we begin with our formal remarks, we do want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent form, 10-K, and other periodic reports filed with the SEC. Ananta does not undertake any obligation to update any forward-looking statements made during this call. I'd now like to turn the call over to Dr. Jay Lulli. Jay?

Thank you, Jennifer. And good afternoon, everyone. At Enanti, our goal has always been to develop curative therapies for patients in need. That effort continues today with our announcement of the top-line data from our Phase II Sprint Study of EDP-235, our 3-CL protease inhibitor, in development as an oral, once-daily treatment for COVID-19. I'll let Dr. Scott Rottinghaus, our Chief Medical Officer, present the data in a minute, but I will highlight a few key points which support our belief that EDP-235 could play an important role in the treatment of COVID-19. First, the trial met its primary endpoint, demonstrating a favorable safety and tolerability profile. In addition, we are excited that the SPRINT data show that EDP-235 had an impact on clinically meaningful endpoints. Scott's presentation will go through this in detail. With that, I'll turn the call over to Scott. Scott?